EP354: Metabolic Syndrome Meeting

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. Podcast Episode Summary Introduction Dr. Warwick Bishop, a cardiologist, author, and CEO of the Healthy Heart Network, hosts this episode to discuss cardiometabolic health—the intersection of heart disease, diabetes, fatty liver disease, and dementia. After addressing listener feedback about a previous episode on the nocebo effect, Dr. Bishop shares key insights from a cardiometabolic academy conference in Melbourne featuring presentations from leading experts in cardiology, lipids, nephrology, hepatology, and neurology. Key Takeaways: Type 1 and Type 2 diabetics carry essentially the same cardiovascular disease risk, contrary to the common assumption that Type 2 diabetics face greater risk. SGLT2 inhibitors (empagliflozin) and GLP-1 agonists (semaglutide/Ozempic) reduce cardiovascular events independently of their effects on glucose control and weight loss, suggesting distinct hormonal mechanisms at play. Prescribers must inform patients starting on SGLT2 inhibitors about rare but serious risks including diabetic ketoacidosis and Fournier's gangrene. Multiple weight loss medications are now available in Australia, with emerging agents like bimagrumab showing promise for weight loss without corresponding muscle mass loss. GLP-1 receptor agonists have receptors throughout the body (pancreas, heart, kidney, brain, stomach, liver), explaining their broad therapeutic effects beyond glucose management. Approximately 50% of people classified as "metabolically healthy overweight" develop diabetes within 10-15 years, challenging the concept of healthy obesity. Fatty liver disease affects roughly one in three people and serves as an early indicator of cardiometabolic disease progression, with early intervention through diet, exercise, and medication potentially preventing serious outcomes. Imaging advances now allow detection of inflammation in arteries and surrounding perivascular fat, which correlates with increased future cardiovascular event risk. GLP-1 agents may help reduce dementia progression by offsetting shared risk factors between Alzheimer's disease and vascular dementia.